Initiates Nasdaq Trading Under New Ticker Symbol “QNCX”
Quince’s ticker symbol on the Nasdaq Stock Market will begin to trade under “QNCX” effective at the open of market trading today, Monday, August 1, 2022. The corporate name change to Quince Therapeutics, Inc. does not affect the rights of the company’s stockholders with respect to the name change. Outstanding stock certificates are not affected by the name change and will not need to be exchanged.
Quince discovered a bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone diseases to promote more rapid healing with fewer off-target safety concerns. Our proprietary science enables the connection of bone-specific targeting molecules to approved drugs, biologics, or radionuclides via small biological linker molecules. The result is the delivery of the proven therapeutic payload directly to the site of disease or injury. Quince’s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site. Preclinical studies demonstrate that this results in rapid increases in bone density, strength and healing directly at the site of injury.
About Quince Therapeutics
Quince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Quince’s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases. The company’s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, which preclinical studies demonstrate result in rapid increases in bone density, strength, and healing directly at the site of bone fracture. NOV004 is expected to enter Phase 1 clinical studies in 2023 and advance to a lead indication in osteogenesis imperfecta. For more information, visit www.quincetx.com and follow Quince Therapeutics on LinkedIn and @Quince_Tx on Twitter.
Quince Therapeutics Contact:
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
601 Gateway Blvd Ste 1250
South San Francisco, CA 94080
|QNCX News: Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury||09/16/2022 08:00:00 AM|
|QNCX News: Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications||09/12/2022 08:00:00 AM|
|QNCX News: Statement of Changes in Beneficial Ownership (4)||09/08/2022 05:59:32 PM|
|QNCX News: Quince Therapeutics Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures||08/30/2022 04:05:00 PM|
|QNCX News: Quince Therapeutics to Present at Upcoming Scientific Meetings||08/25/2022 04:05:00 PM|